Astec LifeSciences Limited Announces Standalone and Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014
January 31, 2015 at 12:29 pm
Share
Astec LifeSciences Limited announced standalone and consolidated unaudited earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the standalone company reported net sales of INR 530.195 million compared with INR 472.871 million for the same period a year ago. Profit from operation before other income, finance cost and exceptional items was INR 81.148 million compared with INR 59.339 million for the same period a year ago. Profit from ordinary activities before tax was INR 36.856 million compared with INR 25.612 million for the same period a year ago. Net profit was INR 37.362 million or INR 1.99 per basic and diluted share compared with INR 22.614 million or INR 1.22 per basic and diluted share for the same period a year ago.
For the nine months, the standalone company reported net sales of INR 1,610.217 million compared with INR 1,474.897 million for the same period a year ago. Profit from operation before other income, finance cost and exceptional items was INR 243.014 million compared with INR 184.318 million for the same period a year ago. Profit from ordinary activities before tax was INR 155.474 million compared with INR 91.413 million for the same period a year ago. Net profit was INR 120.236 million or INR 6.58 per basic and diluted share compared with INR 73.462 million or INR 3.96 per basic and diluted share for the same period a year ago.
For the quarter, the consolidated company reported net sales of INR 572.605 million compared with INR 506.994 million for the same period a year ago. Profit from operation before other income, finance cost and exceptional items was INR 82.061 million compared with INR 59.519 million for the same period a year ago. Profit from ordinary activities before tax was INR 45.913 million compared with INR 24.295 million for the same period a year ago. Net profit was INR 35.927 million or INR 1.91 per basic and diluted share compared with INR 21.3 million or INR 1.15 per basic and diluted share for the same period a year ago.
For the nine months, the consolidated company reported net sales of INR 1,745.415 million compared with INR 1,603.559 million for the same period a year ago. Profit from operation before other income, finance cost and exceptional items was INR 247.012 million compared with INR 189.147 million for the same period a year ago. Profit from ordinary activities before tax was INR 150.758 million compared with INR 88.559 million for the same period a year ago. Net profit was INR 115.355 million or INR 6.31 per basic and diluted share compared with INR 70.608 million or INR 3.90 per basic and diluted share for the same period a year ago.
Astec LifeSciences Limited is an India-based company that is primarily engaged in manufacturing a range of agrochemical active ingredients and pharmaceutical intermediates. The Company operates through the Agrochemicals segment. It manufactures a range of fungicides, insecticides, herbicides, and intermediates for its global customers. The Companyâs products and intermediates includes triazole fungicides, heterocyclic herbicides, sulfonylurea herbicides, synthetic pyrethroids, alkyl and aryl magnesium halides, mixed metal halides, silane derivatives, fluorinated aromatic, aliphatic and heterocyclic intermediates, fluorinated aromatic amines, fluorinated pyridine derivatives, fluorinated aromatic carboxylic acids, fluorinated benzyl alcohols, fluorinated ketones and benzophenones, fluorinated heterocyclic mercaptans, heterocyclic mercaptans, thiopyrimidines, aromatic mercaptans, thorium salts, pyrazaloneâs and heterocyclic sulfonyl chlorides.
Astec LifeSciences Limited Announces Standalone and Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014
ASTEC LIFESCIENCES LIMITED 
